Ovid Therapeutics Inc. Operating Income Loss

• Ovid Therapeutics Inc. showed an increase of +31.4% in Operating Income Loss from 2024 to 2025.
• This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Ovid Therapeutics Inc.'s Operating Income Loss has declined by 221.7%.
• Historical annual values: Fiscal year 2025: -$42.44 million | Fiscal year 2024: -$61.89 million | Fiscal year 2023: -$59.28 million | Fiscal year 2022: -$55.55 million | Fiscal year 2021: $124.21 million | Fiscal year 2020: -$81.43 million | Fiscal year 2019: -$61.41 million | Fiscal year 2018: -$52.93 million | Fiscal year 2017: -$65.01 million | Fiscal year 2016: -$22.54 million | Fiscal year 2015: -$13.19 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026